Ionis Pharmaceuticals (IONS)

Company Description

Ionis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

COMPANY ADDRESS
2855 Gazelle Court
Carlsbad, CA 92010
United States

COMPANY PHONE
760-931-9200

COMPANY WEBSITE



Get BioInvest's perspective on Ionis Pharmaceutical's CEO


Latest Company News

Investor Update: Tracking Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Business Daily - 1 hour ago Taking a quick look at the historical performance of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares, we have noted that the stock price for the previous week is 6.46%. [...]
Tue, Jun 27, 2017 8:32:00 PM, Continue reading at the source
Volatile Stock in Focus: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rover - 5 hours ago Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares have caught our attention after a recent volatility scan. Focusing on the ATR or average true range, we can see that the current level is 1.76. [...]
Tue, Jun 27, 2017 4:29:00 PM, Continue reading at the source
Akcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO Seeking Alpha - 7 hours ago Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceutical, is expected to IPO on Friday, June 30. The company intends to sell 9,620,000 shares with an additional 1,443,000 shares over-allotted as an option for its underwriters. [...]
Tue, Jun 27, 2017 3:00:00 PM, Continue reading at the source
Option Market Alert: Ionis Pharmaceuticals Inc Implied Price Swing Hits An ... CML News - Jun 26, 2017 No Risk Alert Here: Before we dive into any analysis we simply note that Ionis Pharmaceuticals Inc (NASDAQ:IONS) risk is neither elevated nor depressed. [...]
Mon, Jun 26, 2017 12:22:00 PM, Continue reading at the source
BMO Capital Markets Reaffirms “Buy” Rating for Ionis Pharmaceuticals, Inc. (IONS) The Cerbat Gem - Jun 25, 2017 Ionis Pharmaceuticals, Inc. logo BMO Capital Markets restated their buy rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a report issued on Friday, June 2nd. The firm currently has a $59.00 price target on the stock. A number of other ... Ionis Pharmaceuticals, Inc. (IONS) Position Boosted by Comerica Bank - BNB Daily (blog) [...]
Sun, Jun 25, 2017 10:07:00 AM, Continue reading at the source
​Here's What's Important About the Ionis Pharmaceuticals, Akcea IPO Equities.com - Jun 23, 2017 Back in 2015, billion-dollar biotechnology company Ionis Pharmaceuticals Inc. (IONS) formed a privately held subsidiary called Akcea Therapeutics. [...]
Fri, Jun 23, 2017 6:00:00 PM, Continue reading at the source
Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's ... PR Newswire (press release) - Jun 22, 2017 CARLSBAD, Calif., June 22, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with ... Ionis Pharma completes enrollment in early-stage study of IONIS-HTTrx in ... - Seeking Alpha (IONS) Shares Trading up at $54.20 Enrollment in Phase 1/2a Study of… - Highlight Press [...]
Thu, Jun 22, 2017 10:52:00 AM, Continue reading at the source
Ionis Pharmaceuticals Inc Risk Points versus Health Care CML News - Jun 14, 2017 This is a scatter plot analysis of the critical risk points from the option market for Ionis Pharmaceuticals Inc (NASDAQ:IONS) compared to its own past and the Health Care ETF. [...]
Wed, Jun 14, 2017 1:30:00 PM, Continue reading at the source
Why Ionis Pharmaceuticals Inc. Swooned 6% in May Motley Fool - Jun 6, 2017 That was large enough increase to allow the company to report a $0.03 profit. Ionis and its future spin-off Akcea announced upbeat results from the Phase 3 Approach trial. A Look at 2 Trending Stocks: Ionis Pharmaceuticals, Inc. (IONS), BioScrip, Inc ... - Post Analyst The Cowen and Company Reaffirms “Market Perform” Rating for Ionis ... - BangaloreWeekly [...]
Tue, Jun 06, 2017 2:03:00 PM, Continue reading at the source
SPINRAZA® (nusinersen) Approved in the European Union PR Newswire (press release) - Jun 1, 2017 CARLSBAD, Calif., June 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the European Commission (EC) has granted marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular ... Biogen, Ionis Stocks Pop After Europe Approves $125000 Drug - Investor's Business Daily Better Buy: Biogen Inc. vs. Gilead Sciences Inc. - Motley Fool [...]
Thu, Jun 01, 2017 11:46:00 AM, Continue reading at the source